Navigation Links
Improved Allergy Shots Might Be on Horizon
Date:11/3/2011

THURSDAY, Nov. 3 (HealthDay News) -- Allergy shots are time-tested treatments that reduce health care costs and can now provide relief to allergy sufferers within weeks instead of months, according to experts.

And while allergy shots are currently given under the skin (subcutaneously), new methods of allergy immunotherapy are being investigated, delegates heard at this week's annual scientific meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Boston.

Those potential new techniques include:

  • Intralymphatic immunotherapy (ILIT), which involves injecting allergens into a lymph node. Initial research shows that this approach provides a longer-lasting and more effective response, suggesting the dose and length of treatment could be shortened.
  • Epicutaneous immunotherapy (EPIT) involves lightly scraping a patient's skin and then applying a patch that delivers the allergens through the bloodstream.

Accelerated allergy immunotherapy and the cost benefits of immunotherapy were also discussed at the meeting.

Conventional immunotherapy requires patients to receive an allergy shot once or twice a week for about five months. But "rush" and "cluster" immunotherapy methods feature accelerated schedules to shorten that treatment period.

Rush immunotherapy typically involves giving multiple injections to a patient two or three days in a row, but schedules may be shorter or longer based on circumstances. Cluster immunotherapy involves two to four injections, given 30 minutes apart, one day a week for three weeks.

"You shouldn't have to put your life on hold to treat your allergies," Dr. Richard Weber, ACAAI vice president, said in a college news release. "Accelerated schedules offer patients more flexibility, faster results and a treatment plan they are more likely to follow because it reflects their needs and busy lifestyle."

"Research shows accelerated schedules are safe and effective options, and they appeal to patients who do not want to commit to weekly allergy shots for five or six months," he added.

Not only is allergy immunotherapy highly effective, it can save thousands of dollars in health care costs per patient, according to a study presented at the meeting.

Researchers examined Florida Medicaid data and found that children with allergies who received allergy immunotherapy had nearly $6,000 less in health care costs over 18 months than children with allergies who did not receive allergy immunotherapy. Among adults, the amount saved over 18 months was more than $7,000.

Because this research was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.

"Allergy immunotherapy is a well-established, safe and effective treatment. Our research clearly shows that this treatment is also cost effective and these cost benefits occur almost immediately," Cheryl Hankin, president and chief scientific officer of BioMedEcon, said in the news release.

More information

The American Academy of Family Physicians has more about allergy shots.

-- Robert Preidt

SOURCE: American College of Allergy, Asthma and Immunology, news release, Oct. 27, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. New research on improved treatment options and screening strategies for Hepatitis C
2. Thyroid Surgery Linked to Improved Sleep Apnea Symptoms
3. New oncolytic virus shows improved effectiveness in preclinical testing
4. Public reporting hasnt improved transplant centers care
5. Improved method for detecting mutant DNAs
6. Researchers from Boston University receive grant to develop improved virus detection system
7. Toward an improved test for adulterated heparin
8. Improved radical surgery techniques provide positive outcomes for bladder cancer patients
9. Clinic demonstrates improved quality of care resulting in cost savings for Medicare
10. New high-speed 3-D imaging system holds potential for improved cancer screening
11. New study may lead to quicker diagnosis, improved treatment for fatal lung disease
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Improved Allergy Shots Might Be on Horizon 
(Date:9/20/2017)... ... ... “The Trials I Face to Receive God’s Grace”: a mesmerizing take ... goals to better one’s life through God. “The Trials I Face to Receive God’s ... wrong places, found a love for writing. Green feels that expressing his feelings through ...
(Date:9/20/2017)... ... ... Houston, Texas, investment firm CORDA Investment Management, LLC, believes in giving back. ... work and rolled up their sleeves to help with relief efforts. The team picked ... process of rebuilding. , CORDA founder Bonner C. Barnes notes that investment management firms ...
(Date:9/20/2017)... ... September 20, 2017 , ... “The Foggy Road to Moorwick”: the adventures of a young ... creation of published author, Jeanine Liston, a busy mother of five who used her time ... been writing this book for over twenty years. It was a way to give ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... “Monique”: ... into uncomfortable situations. “Monique” is the creation of published author, Colleen Crispi, has owned ... Since then Crispi has been involved in real estate and cooking. , “The ...
(Date:9/19/2017)... ... September 19, 2017 , ... DeSola Group, ... marketing leader, Denise Flannery, to its strategic advisory and client development team. ... will work with clients across different industries to develop and implement market-justified strategies, ...
Breaking Medicine News(10 mins):
(Date:9/9/2017)... 9, 2017  Eli Lilly and Company (NYSE: ... endpoint data for lasmiditan, an investigational, oral, first-in-class molecule ... significant improvements compared to placebo in the Phase 3 ... the 18th Congress of the International Headache Society (IHC) ... data presented today demonstrate lasmiditan,s potential to reduce pain ...
(Date:9/7/2017)... Caris Life Sciences, a leading innovator ... of precision medicine, today announced results from two ... molecular profiling approach in guiding therapeutic strategies in ... (CGP+) with Caris Molecular Intelligence ® to ... level, leading to more therapeutic options and improved ...
(Date:9/7/2017)... , Sept. 7, 2017   BioLife Solutions , Inc. ... marketer of proprietary clinical grade cell and tissue hypothermic ... that Mike Rice , President and CEO, will be ... Rodman & Renshaw 19 th Annual Global ... time (12:25 p.m. Pacific time). The conference is being held ...
Breaking Medicine Technology: